Yahoo Finance Insider Sale: Chief Scientific Officer Percy Carter Sells Shares of Blueprint Medicines Corp (BPMC)
On June 5, 2024, Percy Carter, Chief Scientific Officer of Blueprint Medicines Corp (NASDAQ:BPMC), sold 4,000 shares of the company. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 41,895 shares of the company.
Blueprint Medicines Corp is a biopharmaceutical company focused on the discovery, development, and commercialization of precision therapies for patients with genomically defined diseases. The company's approach aims at targeting specific mutations that cause cancer and other serious diseases.
Over the past year, Percy Carter has sold a total of 8,722 shares and has not made any purchases of the company's stock. This recent transaction is part of a broader trend observed within the company, where there have been 37 insider sells and no insider buys over the past year.
On the valuation front, shares of Blueprint Medicines Corp were trading at $105.13 on the day of the sale. The company has a market cap of $6.47 billion. According to the GF Value, an intrinsic value estimate by GuruFocus, the stock is significantly overvalued with a price-to-GF-Value ratio of 1.34. The GF Value of $78.55 is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This insider sale might interest investors tracking insider behaviors as an indicator of confidence levels concerning the company's current valuation and future prospects.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
